FAK-IN-16 (OXA-11) is an orally active, selective focal adhesion kinase (FAK) inhibitor with an IC50 of 1.2 pM; it inhibits FAK phosphorylation at pFAK[Y397] and pFAK[Y861], suppresses tumor growth, reduces tumor vascularization and invasion, and enhances the antitumor effects of cisplatin (HY-17394) on tumor cell proliferation and apoptosis in vitro as well as in vivo in mice.